Elsevier

Autoimmunity Reviews

Volume 16, Issue 7, July 2017, Pages 722-729
Autoimmunity Reviews

Review
Interstital lung disease in ANCA vasculitis

https://doi.org/10.1016/j.autrev.2017.05.008Get rights and content

Abstract

Anti-neutrophil cytoplasmic antibodies (ANCA) vasculitides are immune-mediated disorders that primarily affect small blood vessels of the airway and kidneys. Lung involvement, one of the hallmarks of microscopic polyangiitis and granulomatosis with polyangiitis, is associated with increased mortality and morbidity. In recent years, several retrospective series and case reports have described the association of interstitial lung disease (ILD) and ANCA vasculitis, particularly those positive for ANCA specific for myeloperoxidase. In the majority of these patients pulmonary fibrosis occurs concurrently or predates the diagnosis of ANCA vasculitis. More importantly, these studies have shown that ILD has an adverse impact on the long-term prognosis of ANCA vasculitis. This review focuses on the main clinical and radiologic features of pulmonary fibrosis associated with anti-neutrophil cytoplasmic antibodies. Major histopathology features, prognosis and therapeutic options are summarized.

Introduction

Anti-neutrophil cytoplasmic antibodies (ANCA) are autoantibodies specific for antigens located in the cytoplasmic granules of neutrophils and lysosomes of monocytes [1]. The two major autoantigen targets are myeloperoxidase (MPO-ANCA) and proteinase 3 (PR3-ANCA). ANCA vasculitides (ANCA-V) are multisystem diseases characterized by necrotizing vasculitis that predominantly affects small vessels [2]. The major clinicopathologic variants of ANCA-V are granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA), and single-organ ANCA-V, including renal-limited ANCA vasculitis (RLV). Pulmonary manifestations are a characteristic feature of ANCA-V [3], with the lung being involved in 85–90% of GPA patients during the course of their disease [4], [5], [6]. The frequency in MPA is slightly lower, with reported prevalence of 25–55% [7], [8], [9]. In both disorders, lung involvement has been associated with unfavorable outcomes [10], [11], [12].

During the last few years, an increasing number of publications have reported the association between interstitial lung disease (ILD) and ANCA vasculitis. The objectives of this review are 1) to describe the main clinical and radiologic manifestations of pulmonary fibrosis (PF) associated with ANCA, 2) to detail major histopathological findings and hypothesize physiopathogenic mechanisms involved in the development of this condition, and 3) to summarize the outcome and therapeutic options for affected patients.

We performed a MEDLINE search for English language articles published between January 1970 and September 2016. The search strategy combined the following terms: “vasculitis, ANCA, granulomatosis with polyangiitis, Wegener's granulomatosis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, Churg-Strauss syndrome, myeloperoxidase or proteinase 3” and “interstitial lung disease, lung fibrosis, pulmonary fibrosis, lung manifestations, thoracic manifestations, interstitial pneumonia or computed tomography (CT)”. Full text of relevant articles were retrieved and reviewed. Additional references quoted in these publications were checked. Data of > 200 patients included in case series [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27] and case reports [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42] constitute the basis of this review.

Section snippets

Epidemiology

Interstitial lung disease associated with ANCA is usually observed in patients older than 65 years old. The average age at presentation seems to be higher in MPA patients with PF than in those with this systemic vasculitis described in general cohorts (66 vs 55 years, respectively) [7], [8], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], but similar to that reported in cases of idiopathic PF (IPF) [43], [44]. Regarding gender, some series have reported a

Clinical manifestations

Major symptoms of patients with ANCA-positive isolated pulmonary fibrosis are progressive dyspnea (50–73%) and nonproductive cough (21–60%) [16], [26], [49], [59]. Other manifestations such as pulmonary hemorrhage and hemoptysis (5%) or constitutional symptoms, i.e., fever (31%) and weight loss (5%) were observed less frequently [16], [49], [58]. In previous studies, ANCA titers did not correlate with the severity of PF [16]. In a small case series, clinical presentation of patients with PF and

Laboratory findings and pulmonary function test

In patients with MPA and ILD, ESR and C-reactive protein (CRP) were increased at disease onset in 95% and 73–79%, respectively [48], [51]. As expected, > 60% of these cases also have abnormal urinalysis [48], [50]. In contrast, marked elevations of ESR and CRP were not described in ANCA-positive PF. In this sense, most studies have found similar CRP levels in patients with initially isolated lung fibrosis irrespective of their ANCA status [16], [56], [58], [59].

Measurement of lung function is an

Imaging

Interstitial lung lesions are a frequent finding in radiologic studies of ANCA-V patients [64]. In a cohort of 150 MPA individuals, CT images obtained before treatment showed that 97% presented at least one lung abnormality, including interstitial lung changes in 66% [64]. Similarly, in another study that included 62 MPO-ANCA cases (51 with MPA), 82% had an abnormal CT scan, 94% of which displayed findings suggestive of interstitial involvement [65]. Most of these interstitial lesions are

Histopathology

The histologic features of pulmonary involvement associated with ANCA vasculitis have been described in detail in previous reports [45], [69]. In these studies, interstitial lesions were a common feature of C-ANCA (usually PR3-ANCA) and P-ANCA (usually MPO-ANCA) patients, observed in 100% and 57% of specimens, respectively [45]. In particular, interstitial fibrosis was documented in 16–48% of the reported patients, being focal in most of the analyzed samples [45], [69]. In 6% of cases,

Pathophysiology

In complex autoimmune diseases such as ANCA vasculitis, diverse mechanisms operate in leading to different disease features, such as glomerulonephritis or pulmonary involvement. Regarding ILD, there are several potential mediators that may contribute to the development of this complication in ANCA vasculitis. Pulmonary fibrosis might be the end result of iterative episodes of intra-alveolar hemorrhage [30], [36], [70]. In this sense, previous series have reported histologic evidence of acute or

Treatment

Treatment of ANCA-V involves induction of remission using highly potent immunosuppressive drugs, followed by a maintenance phase to prevent relapses and chronic damage [83]. Although regimen options for initial therapy of ANCA patients are well established [84], there is limited data on how to treat the particular subset of cases with ILD. In fact, this specific lung problem is not mentioned in recent publications providing recommendations for the management of ANCA-V [84], [85], [86].

Most of

Outcome

ILD has an adverse impact on the long-term prognosis of MPA patients. Most of the series that compare MPA patients with and without PF reported that ILD was associated with poor prognosis and reduced survival [13], [15], [17], [26], [96]. In two recent publications, mortality was 2 to 4 times higher in MPA patients with PF [7], [19]; although this has not been confirmed by others [18].

In the analyzed series of MPA patients with PF, one-third developed chronic respiratory insufficiency requiring

Conclusions

ILD is an uncommon complication of MPO-ANCA and PR3-ANCA vasculitis that is associated with poor prognosis. Most of the time, pulmonary fibrosis develops before or occurs simultaneously with onset of systemic vasculitis symptoms. ANCA vasculitis should be included in the differential diagnosis of “idiopathic” pulmonary fibrosis. ANCA testing should be included in the diagnostic workup of interstitial pneumonia and pulmonary fibrosis both at onset and periodically during the disease course.

Large

Take-home messages

  • Diffuse interstitial lung disease and pulmonary fibrosis may be clinical manifestations of anti-neutrophil cytoplasmic antibodies (ANCA) vasculitis.

  • The most common ANCA associated with ILD are those directed against myeloperoxidase (MPO-ANCA).

  • Pulmonary fibrosis occurs concurrently or precedes to ANCA vasculitis in the majority of affected individuals.

  • Usual interstitial pneumonia (UIP) is the most frequent radiological pattern in ANCA positive disease.

  • Interstitial lung disease has an adverse

Declaration of interest

The authors declare no conflicts of interest.

References (96)

  • A.P. Yu et al.

    Computed tomography image analysis before and after treatment of anti-neutrophil cytoplasmic antibody-associated pulmonary interstitial fibrosis in 8 patients

    Clin Ther

    (2014)
  • M. Ando et al.

    Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis

    Respir Med

    (2013)
  • T. Katsuyama et al.

    Current concept and epidemiology of systemic vasculitides

    Allergol Int

    (2014)
  • K. Gocho et al.

    Microscopic polyangiitis preceded by combined pulmonary fibrosis and emphysema

    Respir Med Case Rep

    (2015)
  • M.W. Peterson et al.

    Prognostic role of eosinophils in pulmonary fibrosis

    Chest

    (1987)
  • Z. Yan et al.

    Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis

    Autoimmun Rev

    (2014)
  • E.J. Mark et al.

    The pulmonary biopsy in the early diagnosis of Wegener's (pathergic) granulomatosis: a study based on 35 open lung biopsies

    Hum Pathol

    (1988)
  • Y. Yoshikawa et al.

    Pulmonary lesions in Wegener's granulomatosis: a clinicopathologic study of 22 autopsy cases

    Hum Pathol

    (1986)
  • J.U. Holle et al.

    Treatment of ANCA-associated vasculitides (AAV)

    Autoimmun Rev

    (2013)
  • D.P. Tashkin et al.

    Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

    Lancet Respir Med

    (2016)
  • S.L. Bosello et al.

    Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis

    Semin Arthritis Rheum

    (2015)
  • P.W. Noble et al.

    Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

    Lancet

    (2011)
  • S.D. Nathan et al.

    Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis

    Lancet Respir Med

    (2017)
  • A.D. Booth et al.

    Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study

    Am J Kidney Dis

    (2003)
  • R.J. Falk et al.

    Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis

    N Engl J Med

    (1988)
  • J.C. Jennette et al.

    2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

    Arthritis Rheum

    (2013)
  • P.H. Nachman et al.

    Pathogenesis of lung vasculitis

    Semin Respir Crit Care Med

    (2011)
  • G.S. Hoffman et al.

    Wegener granulomatosis: an analysis of 158 patients

    Ann Intern Med

    (1992)
  • G. Anderson et al.

    Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee

    Q J Med

    (1992)
  • J.H. Schirmer et al.

    Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort

    Rheumatology (Oxford)

    (2016)
  • L. Guillevin et al.

    Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients

    Arthritis Rheum

    (1999)
  • T.M. Hassan et al.

    Lung involvement at presentation predicts disease activity and permanent organ damage at 6, 12 and 24 months follow-up in ANCA-associated vasculitis

    BMC Immunol

    (2014)
  • S. Furuta et al.

    Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan

    J Rheumatol

    (2014)
  • E. Reinhold-Keller et al.

    An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients

    Arthritis Rheum

    (2000)
  • B. Hervier et al.

    Vasculitis study, pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature

    Ann Rheum Dis

    (2009)
  • T. Nozu et al.

    A comparison of the clinical features of ANCA-positive and ANCA-negative idiopathic pulmonary fibrosis patients

    Respiration

    (2009)
  • G.E. Tzelepis et al.

    Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis

    Eur Respir J

    (2010)
  • N. Arulkumaran et al.

    Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study

    Rheumatology (Oxford)

    (2011)
  • L.F. Flores-Suarez et al.

    Reduced survival in microscopic polyangiitis patients with pulmonary fibrosis in a respiratory referral centre

    Clin Rheumatol

    (2015)
  • M. Fernandez Casares et al.

    Microscopic polyangiitis associated with pulmonary fibrosis

    Clin Rheumatol

    (2015)
  • K. Hiromura et al.

    Four cases of anti-myeloperoxidase antibody-related rapidly progressive glomerulonephritis during the course of idiopathic pulmonary fibrosis

    Clin Nephrol

    (2000)
  • K. Nakabayashi et al.

    Classification of clinical subtypes, patient survival, kidney prognosis, and relapse in patients with MPO-ANCA-associated vasculitis: a single-center experience

    Mod Rheumatol

    (2009)
  • K. Nakabayashi et al.

    Dual myeloperoxidase-antineutrophil cytoplasmic antibody- and antiglomerular basement membrane antibody-positive cases associated with prior pulmonary fibrosis: a report of four cases

    Clin Exp Nephrol

    (2011)
  • A. Shiraki et al.

    Prevalence of myeloperoxidase-anti-neutrophil cytoplasmic antibody (MPO-ANCA) in patients with interstitial pneumonia

    Nihon Kokyuki Gakkai Zasshi

    (2007)
  • S. Homma et al.

    Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides

    Respirology

    (2004)
  • A. Becker-Merok et al.

    Fibrosing alveolitis predating microscopic polyangiitis

    Scand J Rheumatol

    (1999)
  • A. Bhanji et al.

    Pulmonary fibrosis-an uncommon manifestation of anti-myeloperoxidase-positive systemic vasculitis?

    NDT Plus

    (2010)
  • J. Birnbaum et al.

    Microscopic polyangiitis presenting as a “pulmonary-muscle” syndrome: is subclinical alveolar hemorrhage the mechanism of pulmonary fibrosis?

    Arthritis Rheum

    (2007)
  • Cited by (120)

    • Overview of Vasculitides in Adults

      2024, Neuroimaging Clinics of North America
    • 73-Year-Old Man With Dyspnea and Cough

      2023, Mayo Clinic Proceedings
    View all citing articles on Scopus
    1

    MA Alba was supported by Secretaria de Ciencia, Tecnología e Innovación (SECITI), Mexico City, Mexico.

    2

    Kenneth M. Brinkhous Distinguished Professor and Chair. Department of Pathology and Laboratory Medicine, School of Medicine. Chief of Pathology and Laboratory Medicine Services, UNC Hospitals, Executive Director, UNC Nephropathology Division, University of North Carolina at Chapel Hill, 308 Brinkhous-Bullitt Building, CB#7525, Chapel Hill, NC 27599-7525.

    View full text